Cargando…

The OECD program to validate the rat uterotrophic bioassay: an overview.

The Organisation for Economic Co-operation and Development has undertaken an international validation program for the rodent uterotrophic bioassay. This validation program comprised two major parts. The first part was the development of a detailed background review document compiling the existing da...

Descripción completa

Detalles Bibliográficos
Autores principales: Owens, William, Koëter, Herman B W M
Formato: Texto
Lenguaje:English
Publicado: 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241658/
https://www.ncbi.nlm.nih.gov/pubmed/12948895
_version_ 1782125467757707264
author Owens, William
Koëter, Herman B W M
author_facet Owens, William
Koëter, Herman B W M
author_sort Owens, William
collection PubMed
description The Organisation for Economic Co-operation and Development has undertaken an international validation program for the rodent uterotrophic bioassay. This validation program comprised two major parts. The first part was the development of a detailed background review document compiling the existing data on the bioassay's history, the molecular and physiologic basis for the bioassay's mechanistic relevance to detect estrogen agonists and antagonists, a review of important bioassay protocol parameters, and a review of the data generated by in vitro assays, previous uterotrophic bioassays, and developmental and reproductive assays to assess and support the overall predictivity of the uterotrophic bioassay. The second part was an extensive multiyear effort managed by a validation management group to demonstrate the operating characteristics of four protocols. The effort was conducted in two phases. The phase 1 results with the reference agonist ethinyl estradiol (EE) and antagonist ZM 189,154 has been published previously. This Environmental Health Perspectives mini-monograph is devoted to the phase 2 work using five weak estrogen agonists, bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT, as well as the negative substance dibutylphthalate. These data show that all protocols successfully detected increases in uterine weights when a sufficient dose level of the weak agonists was administered, whether the substances were known or provided as coded doses to the laboratory. The data with both the reference EE and all five weak agonists are reproducible over time and under a variety of different experimental conditions (e.g., animal strain, diet, housing, bedding, vehicle, animal age). In conclusion, all protocols now have sufficient data to support their validity.
format Text
id pubmed-1241658
institution National Center for Biotechnology Information
language English
publishDate 2003
record_format MEDLINE/PubMed
spelling pubmed-12416582005-11-08 The OECD program to validate the rat uterotrophic bioassay: an overview. Owens, William Koëter, Herman B W M Environ Health Perspect Research Article The Organisation for Economic Co-operation and Development has undertaken an international validation program for the rodent uterotrophic bioassay. This validation program comprised two major parts. The first part was the development of a detailed background review document compiling the existing data on the bioassay's history, the molecular and physiologic basis for the bioassay's mechanistic relevance to detect estrogen agonists and antagonists, a review of important bioassay protocol parameters, and a review of the data generated by in vitro assays, previous uterotrophic bioassays, and developmental and reproductive assays to assess and support the overall predictivity of the uterotrophic bioassay. The second part was an extensive multiyear effort managed by a validation management group to demonstrate the operating characteristics of four protocols. The effort was conducted in two phases. The phase 1 results with the reference agonist ethinyl estradiol (EE) and antagonist ZM 189,154 has been published previously. This Environmental Health Perspectives mini-monograph is devoted to the phase 2 work using five weak estrogen agonists, bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT, as well as the negative substance dibutylphthalate. These data show that all protocols successfully detected increases in uterine weights when a sufficient dose level of the weak agonists was administered, whether the substances were known or provided as coded doses to the laboratory. The data with both the reference EE and all five weak agonists are reproducible over time and under a variety of different experimental conditions (e.g., animal strain, diet, housing, bedding, vehicle, animal age). In conclusion, all protocols now have sufficient data to support their validity. 2003-09 /pmc/articles/PMC1241658/ /pubmed/12948895 Text en
spellingShingle Research Article
Owens, William
Koëter, Herman B W M
The OECD program to validate the rat uterotrophic bioassay: an overview.
title The OECD program to validate the rat uterotrophic bioassay: an overview.
title_full The OECD program to validate the rat uterotrophic bioassay: an overview.
title_fullStr The OECD program to validate the rat uterotrophic bioassay: an overview.
title_full_unstemmed The OECD program to validate the rat uterotrophic bioassay: an overview.
title_short The OECD program to validate the rat uterotrophic bioassay: an overview.
title_sort oecd program to validate the rat uterotrophic bioassay: an overview.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241658/
https://www.ncbi.nlm.nih.gov/pubmed/12948895
work_keys_str_mv AT owenswilliam theoecdprogramtovalidatetheratuterotrophicbioassayanoverview
AT koeterhermanbwm theoecdprogramtovalidatetheratuterotrophicbioassayanoverview
AT owenswilliam oecdprogramtovalidatetheratuterotrophicbioassayanoverview
AT koeterhermanbwm oecdprogramtovalidatetheratuterotrophicbioassayanoverview